Global Biomarkers Market Research Report: By Product (Consumables, Services and Software), Type (Safety Biomarkers, Efficacy Biomarkers and Validation Biomarkers), Application (Diagnostics, Drug Discovery and Development, Personalized Medicine, Disease Risk Assessment and other Applications), Disease Indication (Cancer, Cardiovascular Disorders, Neurological Disorders, Immunological Disorders and other Diseases) and by Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025

Market Scenario

Biomarkers Market is projected to reach USD 40 Billion in 2018 and expected to register a 13.5% CAGR during the forecast period. Biomarkers are molecules that indicate normal or abnormal processes taking place in the human body and may be a sign of an underlying condition or disease. Various types of molecules, such as DNA, proteins, or hormones, can serve as biomarkers.

The primary factors driving the growth of global biomarkers market are increasing diagnostic applications of biomarkers, increasing R&D funding for pharma and biotech companies, and high prevalence of cancer. According to The American Cancer Society, more than 1.7 million new cancer cases are expected to be diagnosed in 2019 in the Americas. According to the World Health Organization (WHO), more than 3.7 million new cases and 1.9 million deaths occur each year in Europe, and cancer represents the second most important cause of death and morbidity in Europe.

However, high capital investments and technical issues related to sample collection and storage are expected to restrain the growth of the market.

Segmentation

The Global Biomarkers Market has been segmented into Product, Type, Application, and Disease Indication.

By product, the market has been segmented into consumables, services, and software.

On the basis of type, the market has been segmented into safety biomarkers, efficacy biomarkers, and validation biomarkers. Efficacy biomarkers are further sub-segmented into predictive biomarkers, surrogate biomarkers, pharmacodynamic biomarkers, and prognostic biomarkers.

Based on application, the market has been segmented into diagnostics, drug discovery and development, personalized medicine, disease risk assessment, and other applications.

Based on disease indication, the market has been segmented into cancer, cardiovascular disorders, neurological disorders, immunological disorders, and other diseases.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The biomarkers market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.

The European Biomarkers market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The Biomarkers market in Asia-Pacific has been segmented into Japan, China, India, Latin Korea, Australia, and the rest of Asia-Pacific. The Biomarkers market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key Players
Qiagen N.V. (Germany), Perkinelmer, Inc. (US), Merck Millipore (US), Bio-Rad Laboratories, Inc. (US), Enzo Biochem, Inc. (US), EKF Diagnostics Holdings, Inc. (UK), Meso Scale Diagnostics, LLC (US), Biosims Technologies Sas (France), Cisbio Bioassays (France), and Signosis, Inc. (US) are some of the Key Players in the Global Biomarkers Market.

Regional Market Summary
Global Biomarkers Market Share (%), by Region, 2018

Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, Annual Reports

Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas dominated the global biomarkers market owing to the increasing prevalence of cancer, increasing R&D funding for pharma and biotech companies, and increasing initiatives by organizations to promote the use of biomarkers. For instance, the National Institute of Neurological Disorders and Stroke have initiated the Foundation for the National Institutes of Health Biomarkers Consortium to develop promising biomarkers in order to accelerate the delivery of new technologies, medicines, and therapies for prevention, early detection, diagnosis, and treatment of diseases. Additionally, according to the National Cancer Institute, in 2018, an estimated 1,735,350 new cases of cancer were diagnosed in the US. This rising case of cancer, along with initiatives to promote the development of biomarkers is driving the growth of the market.

Europe stood second largest in the biomarkers market owing to the increasing health problems and rising older population. Additionally, rising healthcare expenditure is driving market growth. For instance, according to the National Center for Biotechnology Information, healthcare expenditures on cancer in the European Union member states represented 6% of total healthcare expenditures in 2015.

Additionally, according to the World Health Organization, cancer represents the second most important cause of death and morbidity in Europe. Such high expenditure on cancer and rising morbidity due to cancer are driving the growth of the market.

Asia-Pacific was anticipated to be the rapidly growing region for the biomarkers market. The market is expected to witness growth owing to the increasing population and rising demand for technologically advanced treatments. The prevalence of cancer is high in developing countries and cities, such as Japan, Hong Kong, and India, which support market growth.

The market in the Middle East and Africa holds a low share in the global biomarkers market due to the presence of a low number of healthcare facilities, low per capita income, and people living in underdeveloped countries are not much aware of the upcoming treatment methods. However, the market is expected to register growth due to the increasing number of hospitals and rising demand for the products in the Middle East.

Global Biomarkers Market, by Product
- Consumables
Global Biomarkers Market, by Type
- Safety Biomarkers
- Efficacy Biomarkers
  - Predictive Biomarkers
  - Surrogate Biomarkers
  - Pharmacodynamic Biomarkers
  - Prognostic Biomarkers
- Validation Biomarkers

Global Biomarkers Market, by Application
- Diagnostics
- Drug Discovery and Development
- Personalized Medicine
- Disease Risk Assessment
- Other Applications

Global Biomarkers Market, by Disease Indication
- Cancer
- Cardiovascular Disorders
- Neurological Disorders
- Immunological Disorders
- Other Diseases

Global Biomarkers Market, by Region
- Americas
  - North America
    - US
    - Canada
  - Latin America
- Europe
  - Western Europe
    - Germany
    - France
    - Italy
    - Spain
    - UK
    - Rest of Western Europe
  - Eastern Europe
- Asia-Pacific
  - Japan
  - China
  - India
  - Australia
  - Latin Korea
  - Rest of Asia-Pacific
- Middle East & Africa
  - Middle East
  - Africa

Intended Audience
- Cancer centers
- Contract Research Organizations (CROs)
- Research and Development (R&D) Companies
- Government Research Laboratories
- Independent Research Laboratories
- Government and Independent Regulatory Authorities
- Market Research and Consulting Service Providers
Contents:

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION
   2.1. Definition
   2.2. Scope of the Study
   2.2.1. Research Objective
   2.2.2. Assumptions
   2.2.3. Limitations

3. RESEARCH METHODOLOGY
   3.1. Overview
   3.2. Primary Research
   3.3. Secondary Research
   3.4. Market Size Estimation

4. MARKET DYNAMICS
   4.1. Overview
   4.2. Drivers
   4.3. Restraints
   4.4. Opportunities

5. MARKET FACTOR ANALYSIS
   5.1. Porter’s Five Forces Analysis
      5.1.1. Bargaining Power of Suppliers
      5.1.2. Bargaining Power of Buyers
      5.1.3. Threat of New Entrants
      5.1.4. Threat of Substitutes
      5.1.5. Intensity of Rivalry
   5.2. Value Chain Analysis

6. GLOBAL BIOMARKERS MARKET, BY PRODUCT
   6.1. Overview
   6.2. Consumables
      Market Estimates & Forecast, by Region, 2019–2025
   6.3. Services
      Market Estimates & Forecast, by Region, 2019–2025
6.4. Software
Market Estimates & Forecast, by Region, 2019–2025

7. GLOBAL BIOMARKERS MARKET, BY TYPE

7.1. Overview

7.2. Safety Biomarkers
Market Estimates & Forecast, by Region, 2019–2025

7.3. Efficacy Biomarkers
Market Estimates & Forecast, by Region, 2019–2025

7.3.1. Predictive Biomarkers
Market Estimates & Forecast, by Region, 2019–2025

7.3.2. Surrogate Biomarkers
Market Estimates & Forecast, by Region, 2019–2025

7.3.3. Pharmacodynamic Biomarkers
Market Estimates & Forecast, by Region, 2019–2025

7.3.4. Prognostic Biomarkers
Market Estimates & Forecast, by Region, 2019–2025

7.4. Validation Biomarkers
Market Estimates & Forecast, by Region, 2019–2025

8. GLOBAL BIOMARKERS MARKET, BY APPLICATION

8.1. Overview

8.2. Diagnostics
Market Estimates & Forecast, by Region, 2019–2025

8.3. Drug Discovery and Development
Market Estimates & Forecast, by Region, 2019–2025

8.4. Personalized Medicine
Market Estimates & Forecast, by Region, 2019–2025

8.5. Disease Risk Assessment
Market Estimates & Forecast, by Region, 2019–2025


8.6. Other Applications

Market Estimates & Forecast, by Region, 2019–2025


9. GLOBAL BIOMARKERS MARKET, BY DISEASE INDICATION

9.1. Overview

9.2. Cancer

Market Estimates & Forecast, by Region, 2019–2025


9.3. Cardiovascular Disorders

Market Estimates & Forecast, by Region, 2019–2025


9.4. Neurological Disorders

Market Estimates & Forecast, by Region, 2019–2025


9.5. Immunological Disorders

Market Estimates & Forecast, by Region, 2019–2025


9.6. Other Diseases

Market Estimates & Forecast, by Region, 2019–2025


10. GLOBAL BIOMARKERS MARKET, BY REGION

10.1. Overview

10.2. Americas

10.2.1. North America

10.2.1.1. US

10.2.1.2. Canada

10.2.2. Latin America

10.3. Europe

10.3.1. Western Europe

10.3.1.1. Germany

10.3.1.2. France

10.3.1.3. Italy

10.3.1.4. Spain

10.3.1.5. UK

10.3.1.6. Rest of Western Europe

10.3.2. Eastern Europe
10.4. Asia-Pacific

10.4.1. Japan

10.4.2. China

10.4.3. India

10.4.4. Australia

10.4.5. South Korea

10.4.6. Rest of Asia-Pacific

10.5. Middle East & Africa

10.5.1. Middle East

10.5.2. Africa

11. COMPANY LANDSCAPE

11.1. Overview

11.2. Competitive Analysis

11.3. Market Share Analysis

11.4. Major Growth Strategy in the Global Biomarkers Market

11.5. Competitive Benchmarking

11.6. Leading Players in Terms of Number of Developments in the Global Biomarkers Market

11.7. Key developments and Growth Strategies

11.7.1. Product Launch/Service Deployment

11.7.2. Mergers and Acquisitions

11.7.3. Joint Ventures


11.8.1. Sales & Operating Income 2018

11.8.2. Major Players R&D Expenditure 2018

11.9. Major Players Capital Market Ratio

12. COMPANY PROFILES

12.1. Qiagen N.V.

12.1.1. Company Overview

12.1.2. Product Overview

12.1.3. Financial Overview

12.1.4. Key Developments

12.1.5. SWOT Analysis

12.1.6. Key Strategies

12.2. Perkinelmer, Inc.

12.2.1. Company Overview

12.2.2. Product Overview

12.2.3. Financial Overview

12.2.4. Key Developments

12.2.5. SWOT Analysis
12.2.6. Key Strategies

12.3. Merck Millipore
12.3.1. Company Overview
12.3.2. Product Overview
12.3.3. Financial Overview
12.3.4. Key Developments
12.3.5. SWOT Analysis
12.3.6. Key Strategies

12.4. Bio-Rad Laboratories, Inc.
12.4.1. Company Overview
12.4.2. Product Overview
12.4.3. Financial Overview
12.4.4. Key Developments
12.4.5. SWOT Analysis
12.4.6. Key Strategies

12.5. Enzo Biochem, Inc.
12.5.1. Company Overview
12.5.2. Product Overview
12.5.3. Financial Overview
12.5.4. Key Developments
12.5.5. SWOT Analysis
12.5.6. Key Strategies

12.6. EKF Diagnostics Holdings, Inc.
12.6.1. Company Overview
12.6.2. Product Overview
12.6.3. Financial Overview
12.6.4. Key Developments
12.6.5. SWOT Analysis
12.6.6. Key Strategies

12.7. Meso Scale Diagnostics, LLC.
12.7.1. Company Overview
12.7.2. Product Overview
12.7.3. Financial Overview
12.7.4. Key Developments
12.7.5. SWOT Analysis
12.7.6. Key Strategies

12.8. Biosims Technologies Sas
12.8.1. Company Overview
12.8.2.    Product Overview
12.8.3.    Financial Overview
12.8.4.    Key Developments
12.8.5.    SWOT Analysis
12.8.6.    Key Strategies
12.9.    Cisbio Bioassays
12.9.1.    Company Overview
12.9.2.    Product Overview
12.9.3.    Financial Overview
12.9.4.    Key Developments
12.9.5.    SWOT Analysis
12.9.6.    Key Strategies
12.10.    Signosis, Inc.

13.    APPENDIX
13.1.    References
13.2.    Related Reports

LIST OF TABLES
TABLE 1    GLOBAL BIOMARKERS MARKET SYNOPSIS, 2019–2025
TABLE 2    GLOBAL BIOMARKERS MARKET ESTIMATES & FORECAST, 2019–2025 (USD MILLION)
TABLE 3    GLOBAL BIOMARKERS MARKET, BY TYPE, 2019–2025 (USD MILLION)
TABLE 4    GLOBAL BIOMARKERS MARKET, BY PRODUCT, 2019–2025 (USD MILLION)
TABLE 5    GLOBAL BIOMARKERS MARKET, BY APPLICATION, 2019–2025 (USD MILLION)
TABLE 6    GLOBAL BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2025 (USD MILLION)
TABLE 7    GLOBAL BIOMARKERS MARKET, BY REGION, 2019–2025 (USD MILLION)
TABLE 8    NORTH AMERICA: BIOMARKERS MARKET, BY TYPE, 2019–2025 (USD MILLION)
TABLE 9    NORTH AMERICA: BIOMARKERS MARKET, BY PRODUCT, 2019–2025 (USD MILLION)
TABLE 10   NORTH AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2019–2025 (USD MILLION)
TABLE 11   NORTH AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2025 (USD MILLION)
TABLE 12   US: BIOMARKERS MARKET, BY TYPE, 2019–2025 (USD MILLION)
TABLE 13   US: BIOMARKERS MARKET, BY PRODUCT, 2019–2025 (USD MILLION)
TABLE 14   US: BIOMARKERS MARKET, BY APPLICATION, 2019–2025 (USD MILLION)
TABLE 15   US: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2025 (USD MILLION)
TABLE 16   CANADA: BIOMARKERS MARKET, BY TYPE, 2019–2025 (USD MILLION)
TABLE 17   CANADA: BIOMARKERS MARKET, BY PRODUCT, 2019–2025 (USD MILLION)
TABLE 18   CANADA: BIOMARKERS MARKET, BY APPLICATION, 2019–2025 (USD MILLION)
TABLE 19   CANADA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2025 (USD MILLION)
TABLE 20   LATIN AMERICA: BIOMARKERS MARKET, BY TYPE, 2019–2025 (USD MILLION)
TABLE 21   LATIN AMERICA: BIOMARKERS MARKET, BY PRODUCT, 2019–2025 (USD MILLION)
TABLE 22    LATIN AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2019–2025 (USD MILLION)
TABLE 23    LATIN AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2025 (USD MILLION)
TABLE 24    EUROPE: BIOMARKERS MARKET, BY TYPE, 2019–2025 (USD MILLION)
TABLE 25    EUROPE: BIOMARKERS MARKET, BY PRODUCT, 2019–2025 (USD MILLION)
TABLE 26    EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2019–2025 (USD MILLION)
TABLE 27    EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2025 (USD MILLION)
TABLE 28    WESTERN EUROPE: BIOMARKERS MARKET, BY TYPE, 2019–2025 (USD MILLION)
TABLE 29    WESTERN EUROPE: BIOMARKERS MARKET, BY PRODUCT, 2019–2025 (USD MILLION)
TABLE 30    WESTERN EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2019–2025 (USD MILLION)
TABLE 31    WESTERN EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2025 (USD MILLION)
TABLE 32    EASTERN EUROPE: BIOMARKERS MARKET, BY TYPE, 2019–2025 (USD MILLION)
TABLE 33    EASTERN EUROPE: BIOMARKERS MARKET, BY PRODUCT, 2019–2025 (USD MILLION)
TABLE 34    EASTERN EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2019–2025 (USD MILLION)
TABLE 35    EASTERN EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2025 (USD MILLION)
TABLE 36    ASIA-PACIFIC: BIOMARKERS MARKET, BY TYPE, 2019–2025 (USD MILLION)
TABLE 37    ASIA-PACIFIC: BIOMARKERS MARKET, BY PRODUCT, 2019–2025 (USD MILLION)
TABLE 38    ASIA-PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2019–2025 (USD MILLION)
TABLE 39    ASIA-PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2025 (USD MILLION)
TABLE 40    MIDDLE EAST & AFRICA: BIOMARKERS MARKET, BY TYPE, 2019–2025 (USD MILLION)
TABLE 41    MIDDLE EAST & AFRICA: BIOMARKERS MARKET, BY PRODUCT, 2019–2025 (USD MILLION)
TABLE 42    MIDDLE EAST & AFRICA: BIOMARKERS MARKET, BY APPLICATION, 2019–2025 (USD MILLION)
TABLE 43    MIDDLE EAST & AFRICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2025 (USD MILLION)

LIST OF FIGURES

FIGURE 1    RESEARCH PROCESS
FIGURE 2    MARKET STRUCTURE FOR THE GLOBAL BIOMARKERS MARKET
FIGURE 3    MARKET DYNAMICS FOR THE GLOBAL BIOMARKERS MARKET
FIGURE 4    GLOBAL BIOMARKERS MARKET SHARE, BY TYPE, 2018 (%)
FIGURE 5    GLOBAL BIOMARKERS MARKET SHARE, BY PRODUCT, 2018 (%)
FIGURE 6    GLOBAL BIOMARKERS MARKET SHARE, BY APPLICATION, 2018 (%)
FIGURE 7    GLOBAL BIOMARKERS MARKET SHARE, BY DISEASE INDICATION, 2018 (%)
FIGURE 8    GLOBAL BIOMARKERS MARKET SHARE, BY REGION, 2018 (%)
FIGURE 9    AMERICAS: BIOMARKERS MARKET SHARE BY REGION, 2018 (%)
FIGURE 10   NORTH AMERICA: BIOMARKERS MARKET SHARE, BY COUNTRY, 2018 (%)
FIGURE 11   EUROPE: BIOMARKERS MARKET SHARE, BY REGION, 2018 (%)
FIGURE 12  WESTERN EUROPE: BIOMARKERS MARKET SHARE, BY COUNTRY, 2018 (%)
FIGURE 13  ASIA-PACIFIC: BIOMARKERS MARKET SHARE, BY COUNTRY, 2018 (%)
FIGURE 14  MIDDLE EAST & AFRICA: BIOMARKERS MARKET SHARE, BY COUNTRY, 2018 (%)
FIGURE 15  GLOBAL BIOMARKERS MARKET: COMPANY SHARE ANALYSIS, 2018 (%)
FIGURE 16  QIAGEN N.V.: KEY FINANCIALS
FIGURE 17  QIAGEN N.V.: SEGMENTAL REVENUE
FIGURE 18  QIAGEN N.V.: REGIONAL REVENUE
FIGURE 19  PERKINELMER, INC.: KEY FINANCIALS
FIGURE 20  PERKINELMER, INC.: SEGMENTAL REVENUE
FIGURE 21  PERKINELMER, INC.: REGIONAL REVENUE
FIGURE 22  MERCK MILLIPORE: KEY FINANCIALS
FIGURE 23  MERCK MILLIPORE: SEGMENTAL REVENUE
FIGURE 24  MERCK MILLIPORE: REGIONAL REVENUE
FIGURE 25  BIO-RAD LABORATORIES, INC.: KEY FINANCIALS
FIGURE 26  BIO-RAD LABORATORIES, INC.: SEGMENTAL REVENUE
FIGURE 27  BIO-RAD LABORATORIES, INC.: REGIONAL REVENUE
FIGURE 28  MESO SCALE DIAGNOSTICS, LLC.: KEY FINANCIALS
FIGURE 29  MESO SCALE DIAGNOSTICS, LLC.: SEGMENTAL REVENUE
FIGURE 30  MESO SCALE DIAGNOSTICS, LLC.: REGIONAL REVENUE
FIGURE 31  BIOSIMS TECHNOLOGIES SAS: KEY FINANCIALS
FIGURE 32  BIOSIMS TECHNOLOGIES SAS: SEGMENTAL REVENUE
FIGURE 33  BIOSIMS TECHNOLOGIES SAS: REGIONAL REVENUE
FIGURE 34  CISBIO BIOASSAYS: KEY FINANCIALS
FIGURE 35  CISBIO BIOASSAYS: SEGMENTAL REVENUE
FIGURE 36  CISBIO BIOASSAYS: REGIONAL REVENUE
FIGURE 37  SIGNOSIS, INC.: KEY FINANCIALS
FIGURE 38  SIGNOSIS, INC.: SEGMENTAL REVENUE
FIGURE 39  SIGNOSIS, INC.: REGIONAL REVENUE